Liquidia reports Q2 2025 results: YUTREPIA launch drives $6.5M product revenue, net loss widens

Liquidia Corp

2025-Q2 EPS reported -$0.94 revenue$11,957,000

YUTREPIA (treprostinil) inhalation powder approved by FDA May 23, 2025; commercial launch in June 2025.
Over 900 unique patient prescriptions and 550 patient starts within 11 weeks post-approval.
ASCENT trial interim: median 6MWD improvement 31.5m at Week 16; median dose 159 mcg QID; no drug-related discontinuations.
Cash $173.4M as of June 30, 2025; product revenue $6.5M in Q2 2025 (first YUTREPIA sales).
Net loss $41.6M ($0.49 per share) vs $28.7M ($0.38) in Q2 2024; SG&A up 95% on commercialization and litigation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.